Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Serina has over 17 years of experience in the biopharmaceutical industry
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
Subscribe To Our Newsletter & Stay Updated
